MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

271.00 -8.23 (-2.95%)
Streaming Delayed Price Updated: 3:55 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,807,685
Open 279.00
Bid (Size) 270.96 (2)
Ask (Size) 271.03 (1)
Prev. Close 279.22
Today's Range 270.64 - 281.05
52wk Range 253.30 - 335.88
Shares Outstanding 537,700,000
Dividend Yield 3.51%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval
AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 trial results. 
Via Benzinga
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property

Performance

YTD
+4.5%
+4.5%
1 Month
-6.1%
-6.1%
3 Month
-3.3%
-3.3%
6 Month
-11.4%
-11.4%
1 Year
-18.1%
-18.1%

More News

Read More
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
How Is The Market Feeling About Amgen?
Via Benzinga
Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug
Via Stocktwits
Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron
Via MarketMinute
Topics Economy
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Why Amgen (AMGN) Stock Is Trading Up Today
Via StockStory
Topics Artificial Intelligence
Friday's session: top gainers and losers in the S&P500 index
Via Chartmill
Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle
Via MarketMinute
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Via MarketMinute
EMA Backs Amgen Drug For Rare Autoimmune Disorder
Via Benzinga
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session.
Via Chartmill
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
Via MarketMinute
2 Healthcare Dividend Stocks to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
1 Cash-Producing Stock to Target This Week and 2 Facing Challenges
Via StockStory
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis
Via Benzinga
Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis
From Kyowa Kirin
Via GlobeNewswire
If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Topics Economy
Nvidia Just Went Quantum—And ETFs Are Scrambling To Catch Up
Via Benzinga
Topics ETFs
Why Is Sanofi Stock Falling Thursday?
Via Benzinga
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug
Via Benzinga

Frequently Asked Questions

Is Amgen publicly traded?
Yes, Amgen is publicly traded.
What exchange does Amgen trade on?
Amgen trades on the Nasdaq Stock Market
What is the ticker symbol for Amgen?
The ticker symbol for Amgen is AMGN on the Nasdaq Stock Market
What is the current price of Amgen?
The current price of Amgen is 271.00
When was Amgen last traded?
The last trade of Amgen was at 09/25/25 03:55 PM ET
What is the market capitalization of Amgen?
The market capitalization of Amgen is 145.71B
How many shares of Amgen are outstanding?
Amgen has 146B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story